investigated the synergistic effects of MSTN inhibitors and GLP-1 agonists by administering apitegromab in combination with semaglutide, a GLP-1 agonist, and tirzepatide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, in patients with obesity (NCT06445075)
Editor information Editors and Affiliations Questions Questions Part I 1
Saravanan P, Bell H, Braae UC, et al
Research shows up to 40% of GLP-1 weight loss can be muscle without intervention, but proper protein + strength training preserves 90%+ of lean mass while you lose fat
IGF-1 and BALP negatively correlated with mandibular length across CVMI stages 3 to 5 except in group 5-5 between IGF-1 and mandibular length
According to researchers, such stressful conditions lead to altered measures of immune function & increased susceptibility to a variety of diseases (41)